The drug candidate is datopotamab deruxtecan, an experimental therapy for locally advanced or metastatic non-small cell lung cancer in patients who have been treated with another chemotherapy — such as docetaxel, the standard treatment that is in short supply.
In a news release, AstraZeneca said the study will “continue as planned to assess overall survival with greater maturity.” No new safety concerns were noted in the phase 3 trial, and “some Grade 5 events [deaths] were observed.”
The candidate met its endpoint of progression-free survival.
